- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07951424
Clinical Utility Pilot Of Thyroid GuidePx
The purpose of this research study is learn about the effects of Thyroid GuidePx® on papillary thyroid cancer treatment recommendations when the test result is disclosed after surgery.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Primary Objectives:
To determine the decision impact of Thyroid GuidePx® when results are disclosed postoperatively, defined across three prespecified decision domains:
- Extent of initial surgery (counterfactual): (i) among patients who actually had a total thyroidectomy, through the post-test clinician survey, whether Thyroid GuidePx® results would have changed surgical extent and lobectomy would have been appropriate. This includes patients who underwent intraoperative conversion from lobectomy to total thyroidectomy due to gross extrathyroidal extension or unexpected central nodal metastases. (ii) Among patients who actually had a lobectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, total thyroidectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential treatment escalation.
- Completion thyroidectomy: whether Thyroid GuidePx® results change the recommendation to perform completion thyroidectomy or not to perform completion thyroidectomy.
- Adjuvant RAI: Whether Thyroid GuidePx® results change the recommendation to administer postoperative RAI or not to administer postoperative RAI.
Secondary Objectives:
- To estimate the proportion of decision changes within each prespecified domain and the net direction (escalation vs de-escalation).
- To explore clinician- and patient-reported drivers of decision change.
- To assess postoperative decisional regret following disclosure of Thyroid GuidePx® results using the Decisional Regret Scale (DRS), and to explore associations with surgical extent and molecular risk category.
- To compare the proportion of patients who had a completion thyroidectomy in patients who underwent Thyroid GuidePx® testing to historical controls.
- To compare recurrence outcomes in patients whose treatment was de-escalated based on Thyroid GuidePx® result to matched historical controls at the same institution.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Anastasios Maniakas, MD
- Número de teléfono: 713-792-4351
- Correo electrónico: amaniakas@mdanderson.org
Ubicaciones de estudio
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- UT MD Anderson
-
Contacto:
- Anastasios Maniakas, MD
- Número de teléfono: 713-792-4351
- Correo electrónico: amaniakas@mdanderson.org
-
Investigador principal:
- Anastasios Maniakas, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
UT MD Anderson
Descripción
Inclusion Criteria:
disease who can potentially be treated with lobectomy will be recruited to the study. Lobectomy-candidate status is determined by the treating physician using standard institutional criteria (e.g., tumor 1-4 cm, cN0/Nx, no gross ETE). Patients may still undergo total thyroidectomy as part of shared decision-making.
Inclusion criteria:
-
Patients aged 18 years or older at the time of enrollment
-
English-speaking
-
Bethesda V or VI cytology following FNA of a thyroid nodule (papillary thyroid cancer)
-
Preoperative candidacy for lobectomy
- Tumor 1 - 4 cm in size
- No known nodal metastasis
- No gross extrathyroidal extension (ETE) on ultrasound
-
Any of the following intraoperative or surgeon-dependent variations are permitted:
- Prophylactic ipsilateral central neck dissection performed at the surgeon's discretion
- Therapeutic central neck dissection for unexpected central node metastases
- Intraoperative conversion to total thyroidectomy (e.g., gross ETE, multiple large central nodes)
-
Able to undergo intraoperative FNA collection for research testing
Exclusion Criteria:
- Prior thyroid operation
- Distant metastatic disease
- Personal history of thyroid cancer
- History of whole-body radiation exposure or radiation to the head and neck region
- Preoperatively known central or lateral lymph node metastasis
- Receipt of total thyroidectomy is not an exclusion if preoperative features otherwise meet lobectomy-candidate criteria
Patients remain eligible if unexpected central nodal disease is identified intraoperatively or if the surgeon elects to perform a prophylactic ipsilateral central neck dissection, as these scenarios are compatible with initial lobectomy candidacy at MD Anderson.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: CASE_ONLY
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
All Patients
Eligible participants will be identified during standard preoperative evaluation for thyroid nodules or confirmed PTC, following cytological diagnosis (Bethesda V or VI). |
Participants will be offered enrollment in this study, in which Thyroid GuidePx® will be performed on an intraoperative FNA (ioFNA) collected during surgery, with results disclosed postoperatively. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Decision Impact. There are three domain-specific endpoints
Periodo de tiempo: Through study completion; an average of 1 year
|
Extent of initial surgery (counterfactual). (i) Among patients who actually had total thyroidectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, would have changed surgical extent. Specifically, if lobectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential de-escalation. (ii) Among patients who actually had a lobectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, total thyroidectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential treatment escalation. b) Completion thyroidectomy. Proportion with a change in recommendation (Yes→No or No→Yes). c) Adjuvant RAI. Proportion with a change in recommendation (Yes→No or No→Yes) and intended dose if Yes. |
Through study completion; an average of 1 year
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Anastasios Maniakas, MD, UT MD Anderson
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Neoplasias por sitio
- Neoplasias
- Neoplasias por tipo histológico
- Neoplasias de tiroides
- Neoplasias de glándulas endocrinas
- Neoplasias de Cabeza y Cuello
- Neoplasias Glandulares y Epiteliales
- Adenocarcinoma
- Carcinoma
- Enfermedades de la tiroides
- Adenocarcinoma Papilar
- Cáncer De Tiroides Papilar
Otros números de identificación del estudio
- 2026-0272
- NCI-2026-08256 (Otro identificador: NCI-CTRP Clinical Trials Registry)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .